bioAffinity Technologies Sees Progress in Lung Cancer Diagnostics
In a significant leap forward for lung cancer detection, bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a pioneering biotechnology firm, has announced that its patent application has been accepted by the Australian Patent Office. This patent pertains to an innovative method for predicting the likelihood of lung cancer through its cutting-edge diagnostic test, CyPath® Lung.
Understanding the Importance of CyPath® Lung
CyPath® Lung utilizes advanced flow cytometry combined with artificial intelligence (AI) technology to analyze sputum samples effectively. This noninvasive test plays a critical role in early-stage lung cancer detection by identifying specific cell populations indicative of cancerous changes. The acceptance of this patent not only enriches bioAffinity's portfolio but also signifies a notable milestone in enhancing lung cancer diagnostics.
The patent application, titled “Detection of Early-Stage Lung Cancer in Sputum Using Automated Flow Cytometry and Machine Learning,” represents a significant intellectual property asset for bioAffinity Technologies, which currently boasts 17 awarded U.S. and international patents along with 38 pending applications targeted at its diagnostic solutions and cancer therapies.
Addressing Global Health Challenges
According to bioAffinity’s President and CEO, Maria Zannes, lung cancer remains one of the leading causes of cancer-related deaths globally. Zannes remarked, "Lung cancer is a global problem that requires global solutions like our noninvasive diagnostic CyPath® Lung that detects the leading cancer-killer at an early stage when treatment can lead to cures." This highlights the urgency and necessity for reliable diagnostic methods that the company strives to deliver.
Implications of the Patent Acceptance
Once the Australian patent is officially issued, it will offer a protective mechanism for the CyPath® Lung diagnostic as a unique assessment tool for lung cancer detection until it expires in 2042. This patent marks the second awarded for this specific test, underscoring its significance in the medical community.
The path to patent issuance typically proceeds automatically three months after acceptance, barring any opposition from third parties that may challenge its validity. bioAffinity Technologies remains committed to defending its intellectual property to secure its innovations.
How CyPath® Lung Works
The efficacy of CyPath® Lung is underscored by recent clinical study results, which showcased remarkable statistics: 92% sensitivity, 87% specificity, and 88% accuracy in diagnosing lung cancer in patients deemed at high risk. The test can detect malignancy in lung nodules smaller than 20 millimeters, marking a crucial advancement in early cancer intervention.
These outcomes contribute significantly to improving patient survival rates, emphasizing the importance of expeditious diagnosis and treatment in lung cancer cases. CyPath® Lung utilizes a fluorescent porphyrin that selectively targets cancer cells, thereby assisting in its identification during laboratory evaluations.
Commitment of bioAffinity Technologies
bioAffinity Technologies dedicates its resources to addressing a pressing need in healthcare—the noninvasive diagnosis of early-stage lung cancer and the development of broad-spectrum cancer therapies. The company’s suite of innovative testing solutions continues to evolve, leveraging cutting-edge technology and research to improve patient outcomes.
With the CyPath® Lung test marketed as a Laboratory Developed Test (LDT), bioAffinity Technologies collaborates with Precision Pathology Laboratory Services, a subsidiary focused on bringing these pioneering diagnostics to clinical practice.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is at the forefront of noninvasive diagnostic solutions aimed at identifying early-stage cancers and other lung-related diseases. By harnessing advanced technology, their products particularly focus on improving detection and treatment methodologies, paving the way for enhanced patient care and survival rates.
With its commitment to innovation, bioAffinity Technologies is significantly contributing to the medical landscape by addressing critical health challenges related to lung cancer through early diagnostics and robust therapeutic approaches.
Frequently Asked Questions
What is CyPath® Lung?
CyPath® Lung is a noninvasive diagnostic test developed by bioAffinity Technologies for the early detection of lung cancer through analysis of sputum samples.
How does CyPath® Lung work?
The test uses advanced flow cytometry and artificial intelligence to analyze sputum and identify cell types associated with malignancy.
What are the benefits of the new patent?
The patent provides bioAffinity Technologies with intellectual property protection for its unique diagnostic method, enhancing its market position and potential for innovation.
What does the clinical study indicate about CyPath® Lung?
Recent studies indicate that CyPath® Lung has a sensitivity of 92%, specificity of 87%, and accuracy of 88% for detecting lung cancer in at-risk patients.
How does this affect lung cancer patients?
This advancement allows for earlier detection and treatment, ultimately improving survival rates and patient outcomes in lung cancer care.
